https://charts.traderzeitung.de/phases/US00847G8042 string(1426) "{"isin":"US00847G8042","name":"Agenus Inc","stock_id_xnas":7873119,"stock_id_xnys":null,"generated_at":"2026-09-24 01:33:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.32,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":8.3,"close_at":"2026-09-21 23:06:00","complete":true,"perf_pct":-0.2404}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":8.26,"close_at":"2026-09-22 15:29:00","complete":true,"perf_pct":-0.4819},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.695,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":5.2663},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.405,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-3.3353},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Agenus Aktie News & Nachrichten

[WKN: A403RK | Symbol: AGEN]

Realtimekurs

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Agenus gefunden werden.

Agenus Nachrichtenticker öffnen

MT Newswires 18.09.2026 12:19 Uhr

Research-Alert: Chardan nimmt Agenus mit Buy und Kursziel von 40 USD auf

MT Newswires 07.08.2026 22:52 Uhr

Agenus beantragt den Wiederverkauf von bis zu 78 Millionen Aktien

04:51 PM EDT, 08/07/2026 (MT Newswires) -- Agenus (AGEN) hat am Freitag eine Registrierungserklärung für den potenziellen Wiederverkauf von bis zu 78

MT Newswires 30.07.2026 16:30 Uhr

--B. Riley passt Kursziel für Agenus von $8 auf $14 an, belässt Buy-Rating

MT Newswires 13.07.2026 12:48 Uhr

Agenus unterzeichnet Vereinbarung zum Verkauf von Wertpapieren im Wert von bis zu 340 Millionen US-Dollar; Aktien steigen vorbörslich

06:47 AM EDT, 07/13/2026 (MT Newswires) -- Agenus (AGEN) hat eine Vereinbarung zum Verkauf von Wertpapieren im Wert von bis zu 340 Millionen US-Dollar

MT Newswires 06.07.2026 14:23 Uhr

Agenus' potenzielle Darmkrebs-Kombination zeigt 21,2 Monate Überleben

08:22 AM EDT, 07/06/2026 (MT Newswires) -- Die dreijährige Phase-1b-Studie von Agenus (AGEN) mit 123 Patienten zu ihrem Medikament Botensilimab plus B